bluebird bio, Inc. (BLE.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 05:13PM CEST. Market open.
| Previous close | 15.90 |
| Open | 15.85 |
| Bid | 0.00 x 12000 |
| Ask | 0.00 x 12000 |
| Day's range | 15.85 - 15.90 |
| 52-week range | 15.31 - 49.99 |
| Volume | |
| Avg. volume | 103 |
| Market cap | 1.075B |
| Beta (5Y monthly) | 1.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Could The bluebird bio, Inc. (NASDAQ:BLUE) Ownership Structure Tell Us Something Useful?
If you want to know who really controls bluebird bio, Inc. ( NASDAQ:BLUE ), then you'll have to look at the makeup of...
- Simply Wall St.
bluebird bio, Inc. (NASDAQ:BLUE) Analysts Just Trimmed Their Revenue Forecasts By 15%
The latest analyst coverage could presage a bad day for bluebird bio, Inc. ( NASDAQ:BLUE ), with the analysts making...
- Motley Fool
Why Bluebird Bio Stock Is Crashing Today
Shares of Bluebird Bio (NASDAQ: BLUE) were crashing 23.3% lower as of 12:18 p.m. EDT on Monday. Bluebird said that the U.S. Food and Drug Administration (FDA) has placed a phase 3 study featuring eli-cel (also known as Lenti-D) on clinical hold. The company also stated that it plans to focus only on the U.S. market with its severe genetic disease products and pull out of the European market.
© 2022 Yahoo. All rights reserved.
